Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  BIOLASE Inc    BIOL

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

BIOLASE Inc : BIOLASE Expects to Report Positive Cash Flow From Operations for Q4 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
01/22/2013 | 02:44pm CET
BIOLASE Expects to Continue to Generate Positive Cash Flow From Operations for 2013 Overall

IRVINE, CA -- (MARKETWIRE) -- 01/22/13 -- BIOLASE, Inc. (NASDAQ: BIOL), the world's leading dental laser manufacturer and distributor, announced today that based on preliminary unaudited financial results, the Company expects to report that it generated positive cash flow from operations for Q4 2012.

"We are pleased with our preliminary unaudited financial results for Q4 2012. It is rewarding to see that our restructuring efforts over the past two years have enabled us to turn the Company around and that we are making significant progress toward achieving our financial goals," said Federico Pignatelli, Chairman and CEO. "The trends we are seeing in the adoption of dental lasers also give us confidence in achieving continued double-digit growth of our core dental franchise. Based on our current plans, we expect the Company will continue to generate positive cash flow from operations for the overall year ending December 31, 2013."

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate approximately 290 patented and patent-pending technologies designed to provide biological treatment and clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment and CAD/CAM systems. BIOLASE has sold more than 21,000 lasers.

Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolaseinc, Twitter at twitter.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

For further information, please contact:
Lisa Wilson
In-Site Communications, Inc.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOLASE INC
11/30 BIOLASE, INC : Other Events, Financial Statements and Exhibits (form 8-K)
11/30 BIOLASE : Announces Expiration of Rights Offering
11/22 BIOLASE : to Conduct Demos of Portable Waterlase Express™ All-Tissue Laser..
11/21 BIOLASE : to Present at the Singular Research Best of the Uncovered 12th Annual ..
11/17 BIOLASE INC : BIOLASE to Present at the LD Micro 10th Annual Main Event Conferen..
11/16 BIOLASE : to Present at the Singular Research Best of the Uncovered 12th Annual ..
11/13 BIOLASE, INC : Change in Directors or Principal Officers (form 8-K)
11/09 BIOLASE : Appoints Richard B. Lanman to Board of Directors
11/09 BIOLASE, INC : Entry into a Material Definitive Agreement, Other Events, Financi..
11/09 BIOLASE : Announces Commencement of Rights Offering
More news
News from SeekingAlpha
12/08 DAILY INSIDER RATINGS ROUND UP 12/6/ : Aat, crk, tep, psec
12/01 Healthcare events next week
11/03 BIOLASE subscription rights entitle shareholders to buy stock at 20% discount
11/01 BIOLASE's (BIOL) CEO Harold Flynn on Q3 2017 Results - Earnings Call Transcri..
11/01 Biolase misses by $0.01, misses on revenue
Financials ($)
Sales 2017 48,1 M
EBIT 2017 -17,6 M
Net income 2017 -18,3 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 -
Capi. / Sales 2017 0,69x
Capi. / Sales 2018 -
Capitalization 33,0 M
Duration : Period :
BIOLASE Inc Technical Analysis Chart | BIOL | US0909111082 | 4-Traders
Technical analysis trends BIOLASE INC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Average target price 1,63 $
Spread / Average Target 275%
EPS Revisions
Harold C. Flynn President, Chief Executive Officer & Director
Jonathan T. Lord Chairman
Richard R. Whipp Vice President-Operations
John R. Beaver Chief Financial Officer & Senior Vice President
Dmitri Boutoussov Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOLASE INC-69.57%33
DANAHER20.95%65 387
ROYAL PHILIPS12.16%36 149